Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations (Q39642171)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 19, 2010

Language	Label	Description	Also known as
English	Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations	scientific article published on October 19, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations (English)

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

1 reference

based on heuristic

inferred from title

antineoplastic resistance

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20959484

5 August 2024

author name string

Chizuko Yamamoto

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Yuji Basaki

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Akihiko Kawahara

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kazutaka Nakashima

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Masayoshi Kage

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hiroto Izumi

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kimitoshi Kohno

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hidetaka Uramoto

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kosei Yasumoto

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Michihiko Kuwano

10

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Mayumi Ono

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

19 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Loss_of_PTEN_Expression_by_Blocking_Nuclear_Translocation_of_EGR1_in_Gefitinib-Resistant_Lung_Cancer_Cells_Harboring_Epidermal_Growth_Factor_Receptor_Activating_Mutations/22386689/1/files/39832157.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20959484

5 August 2024

http://cancerres.aacrjournals.org/cgi/content/abstract/70/21/8715

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20959484

5 August 2024

https://aacrjournals.org/cancerres/article-pdf/70/21/8715/2644695/8715.pdf

Portable Document Format

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

8715-8725

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.1141478

Global cancer statistics in the year 2000.

1

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

One hundred years of lung cancer

2

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

3

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

4

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

5

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

7

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

8

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

9

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

10

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs

11

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer

12

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells

13

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

14

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

15

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors

16

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

17

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

18

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

19

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

KRAS mutations in non-small cell lung cancer

20

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

22

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

23

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

24

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

25

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis

26

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

27

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

28

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

PTEN expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells.

29

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

APE1/Ref-1 regulates PTEN expression mediated by Egr-1

30

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival

31

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Transforming Growth Factor-α Enhances Cyclin D1 Transcription through the Binding of Early Growth Response Protein to a cis-Regulatory Element in the Cyclin D1 Promoter

32

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: role for transcription factor EGR1.

33

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation

34

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Basic fibroblast growth factor transcriptional autoregulation requires EGR-1.

35

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase

36

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Why is PTEN an important tumor suppressor?

37

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation

40

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

The biology and clinical relevance of the PTEN tumor suppressor pathway

41

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling

43

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization

44

1 reference

10.1158/0008-5472.CAN-10-0043

https://api.crossref.org/works/10.1158/0008-5472.CAN-10-0043

5 August 2024

Identifiers

10.1158/0008-5472.CAN-10-0043

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39642171&oldid=2222740362"